X-SCID, the most common form of human SCID, is due to mutations in the common y chain gene (yc) that encodes an essential component of the cytokine receptors for interleukin-2 (IL-2). IL-4, IL-7, IL-9, and IL-15. Activation of the Janus familytyrosine kinases Jakl and Jak3 is necessary for appropriate signalling through the IL-2 receptor (IL-2R). Neither Jakl nor Jak3 was phosphorylated after IL-2 stimulation of an Epstein-Barr virus-transformed cell line (LCL) from an X-SCID patient with a -yo null mutation. However, we now show that appropriate IL-2R function can be restored in an EVERE COMBINED immune deficiency (SCID) is a S syndrome marked by the absence of antigen-specific Tand B-lymphocyte function. X-linked SCID (X-SCID) is the cause of approximately 25% to 50% of all cases of SCID.' X-SCID is due to mutations in the common y ( y c ) receptor gene.'.' In about one-third of patients, there is no detectable y c transcript, whereas two-thirds of patients express a ycspecific
2RP and yc chains, respectively, and the association between Jak3 and yc increases upon IL-2 stimulation.".22
The present work shows successful reconstitution of cytokine receptor-mediated signalling in X-SCID lymphoblastoid cell lines after retroviral-mediated transduction of the wild-type yc gene. Jak3 as well as Jakl are phosphorylated in response to IL-2 in the transduced cells although neither tion. 14,16, 17 Jakl and J& '3.",14,19-21 X-SCID LCL by transduction of a wild-type yc gene. A retroviral vector, Gly.SvNa, was constructed and produced in the PG13 packaging line. Transduced X-SCID LCL expressed the G I ycSvNa transcript. IL-2 stimulation of the transduced cell line resulted in appropriate tyrosine phosporylation of both Jakl and Jak3. Thus, retroviral-mediated transduction of normal yc can reconstitute downstream signalling through the IL-2R in X-SCID cell lines, suggesting that gene therapy may be a treatment for this disease. Janus kinase is activated in X-SCID LCL. Such preclinical studies are essential for evaluating the feasibility of gene therapy for X-SCID.
MATERIALS AND METHODS
Construction of the GI y,SvNa vector. The normal yc cDNA was obtained by reverse transcription-polymerase chain reaction (RT-PCR) of RNA from the peripheral blood mononuclear cells of a normal individual. The yc sequences of the PCR primers were 5'-CCATG'ITGAAGCCATCATTA-3' and 5'-AGGACCCTGGGG-'ITCTTCTG-3', which generate a 1,233-bp product containing a yc sequence from -12 bp to +1218 bp. 6 The primers contained additional 5' BamHI and Bgl I1 restriction sites. The PCR product was cloned into pBluescript SK (Stratagene, San Diego, CA) and sequenced. The inserted fragment was digested with Not I and Sal I and cloned into the respective Not and Sal I sites of the pGlXSvNa vector plasmid, a derivative of LXSN (from Genetic Therapy, Inc, Gaithersburg, MD).
To generate a high-titer packaging line, the resultant pG1 y,SvNa plasmid was transfected into the gp+env 86 ecotropic packaging linez3 using DOTAP reagent (Boehringer Mannheim, Indianapolis, IN), as previously de~cribed.'~ Supernatants from the ecotropic line were then used to infect PG13 amphotropic packaging cells.*' The infected PG13 cells were cloned in 0.5 mg/mL G418 (geneticin; GIBCO BRL, Gaithersburg, MD). A single clone with a titer of 2 (LCL). Fluorescence in situ hybridization (FISH) analysis with a Ychromosome-specific probe was used to confirm that the JT cell line was derived from the patient (rather than from matemal engraftment). EBV-transformed LCLs from normal individuals were used as controls. HUT 78 cells were obtained from the ATCC (Rockville, MD). The cell lines were cultured in RPMI 1640 with 10% fetal calf serum, 2 mmol/L glutamine, 50 U/mL penicillin, and 50 pg/mL streptomycin.
Retroviral transductions. Supematants from the G 1 y,SvNa PG13 packaging line were added at 1:l dilution to JT cells in logarithmic growth phase ( I X IO-' cells/ml) in the presence of 3 pgl mL protamine. Fresh viral supematants were added every 24 hours for 3 successive days. The JT cells were then diluted to approximately 5 X IO4 cellslmL and I-mL aliquots were seeded into wells of a 24-well plate. After 24 hours, G418 was added to a final concentration of 400 pglmL. In four different transductions, approximately 3 to 6 wells from each plate grew after 2 to 3 weeks in G418. Northern blot analysis was used to confirm the expression of the GI y,SvNa retroviral gene, using the yc and neomycin phosphotransf e m e genes as probes. Control cells were transduced with the LN vector that contains only the neomycin phosphotransferase gene."
Cells were stimulated essentially as previously described." Briefly, after washing twice in Hank's Buf- were immunoprecipitated with the specified antibody for 2 hours at 4°C. A rabbit polyclonal antibody to Jak3 was the gracious gift of John O'Shea (National Institutes of Health, Bethesda, MD) while monoclonal and polyclonal antibodies to Jakl were purchased from Transduction Laboratories (Lexington, KY) and Santa Cruz Biotechnology Inc (Santa Cruz, CA), respectively. The immunoprecipitates were collected on protein N G agarose (Santa Cruz Biotechnology Inc) for 1 hour at 4°C. Unbound proteins were removed by three washes in lysis buffer. Immunoprecipitates were eluted by boiling in 2X sodium dodecyl sulfate (SDS) sample buffer.
The immunoprecipitates were then separated on 7.5% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) gels and transferred electrophoretically to a Hybond membrane (Amersham, Arlington Heights, IL). Membranes blotted with the 4G10 antiphosphotyrosine antibody (Upstate Biotechnology Inc, Lake Placid, NY) were blocked in TBS (150 mmolL NaCI, 20 mmol/L Tris, pH 7.5) containing 2% bovine serum albumin (BSA) and 0.05% Tween-20, whereas filters blotted with all other antibodies were blocked in TBS with 5% BSA and 0.1% Tween 20. Blots were incubated with the specified antibody for 1 hour at room temperature with continuous agitation. Blots incubated with the 4G10 antiphosphotyrosine antibody were washed with TBS containing 0.05% Tween 20, whereas all other blots were washed with TBS containing 0.1% Tween 20. Blots were then incubated for 1 hour with either a horseradish peroxidase conjugated antirabbit or antimouse antibody (Amersham) and visualized using the enhanced chemiluminescence (ECL) detection system (Amersham). For reblotting, filters were stripped in 0.1 mol/ L glycine, pH 2.5, for I hour at room temperature and blocked before probing with a second antibody.
IL-2-mediated signalling.

RESULTS
GI y,SvNa vector.
The map of the G1 y,SvNa vector is shown in Fig 1. The 1,233-bp yc cDNA was cloned into the BamHI sites of pBS and a clone was selected with the 5' end oriented at the Not I site and the 3' end at the Sa/ I site. The sequence of the y c cDNA used for construction of the vector has a conserved C + T polymorphism at basepair 153, which does not change the Ser codon at amino acid position 51. The yc cDNA was cloned into the Not I and Sal I sites of the pGlXSvNA plasmid. Transcription of the yc cDNA is under the control of the Moloney LTR, whereas an internal SV40 promotedenhancer controls the transcription of the neomycin phosphotransferase gene, which was used as a selectable marker.
The JT cell line is an EBV-transformed LCL from a patient with X-SCID. Northern blot analysis, using the entire yc PCR product described above as a probe, was performed to determine whether the JT cells express yc. In contrast to normal LCLs, there was no 1.8-kb yc transcript detected in the JT cell line (Fig 2) . RT-PCR, using the same primers described for the cloning of the yc cDNA above, also showed no transcript (data not shown). Thus, JT cells contain a null mutation that completely abrogates yc expression.
Normalization of y,. mRNA expression by transduction with GIy,SvNa. JT cells were transduced with the G 1 y,SvNa vector to test the ability of retroviral-mediated y c gene transfer to restore normal IL-2R function. Pools of JT cells from two different transduction experiments were selected in G418 to obtain cells containing GI y,SvNa (JT/ y e cells). Northem blots showed the presence of a y,-specific transcript in the JTly, cells, corresponding to the expected full-length 4.6-kb G1 y,SvNa transcript, as observed in the PG13/GI y,SvNa packaging cell line (Fig 2) . Additionally, an alternatively spliced y,-specific mRNA was detected in the JTly, cells. In contrast, the endogenous 1.8-kb yc transcript was only observed in control LCL. Thus, y e expression in the G l y,SvNa-transduced cells was exclusively the result of retroviral mediated transduction of the wild-type y c gene.
IL-2 induction of Jak3 phosphorylation in GI y,.SvNutransduced JT cells. To determine whether retrovirally mediated transduction of y c can correct receptor function, nontransduced and transduced cells were stimulated with IL-2 and downstream signalling was analyzed. Both normal and JT LCL express equivalent amounts of IL-2Ra and IL-2R,6, as measured by flow cytometry (data not shown); thus, restoration of y c expression in JT cells may result in normal IL-2R function. After the addition of IL-2, Jak3 was immunoprecipitated from cell lysates, separated on 7.5% SDS-PAGE gels, and immunoblotted with an antiphosphotyrosine antibody. Jak3 was not tyrosine phosphorylated in the nontransduced JT cells or JT transduced with the LN vector after IL-2 stimulation (Fig 3, top panel, and data not shown) . In contrast, Jak3 was phosphorylated after IL-2 induction to levels equivalent to that observed in control LCL lines and approximately 50% of that observed in a T-cell line (HUT 78; Fig 3 and data not shown) . Uniformity of Jak3 immunoprecipitation from uninduced and IL-2-induced cell lysates was shown by immunoblotting with a Jak3 polyclonal antibody (Fig 3, bottom panel) .
IL-2 induction of Jakl phosphorylation in GI y,.SvNatransduced JT cells. Jak3 normally associates with y'11.2L 
5' LTR
and correction of IL-2R-mediated phosphorylation of Jak3 in the transduced JT cells was observed. However, in contrast to Jak3, Jakl associates with IL-2RP and has no direct association with yc.ll.22 Thus, it was important to assess the effect of a null yc mutation on Jakl phosphorylation. We found that induction of Jakl phosphorylation, like that of Jak3, was dependent on yc. After the addition of IL-2, Jakl was not tyrosine phosphorylated in the nontransduced JT cells or JT transduced with the LN vector (Fig 4, top panel and data not shown). JTly, cells showed IL-2-induced tyrosine phosphorylation of Jakl, to approximately 50% of the level kb observed in HUT 78 cells (relative to the amount of Jakl immunoprecipitated in the two cell types ; Fig 4) . Thus, the phosphorylation of Jakl after stimulation of the IL-2R is dependent on the presence of a wild-type yc.
DISCUSSION
We have shown that retrovirally mediated transduction of the yc cDNA into an X-SCID cell line lacking any yc expres- sion results in formation of a functional IL-2R, as assessed by the level of y E mRNA, as well as by the IL-2-induced tyrosine phosphorylation of Jakl and Jak3.
Analysis of IL-2R-mediated signalling has shown specific roles for each receptor chain in ligand binding and signal transduction.' '.''."x The NHZterminus of the IL-2Ra chain is important for ligand binding, but the short (13aa) cytoplasmic domain makes assciation with cytoplasmic signalling moelcules ~n1ikely.l~ The IL-2RP chain and yI. are both members of the cytokine receptor superfamily, but have different abilities to mediate signal transduction." The IL-2RP chain is constitutively associated with Jakl, whereas IL-2 increases association of Jak3 with yc."." It was not previously known whether Jak3 as well as Jakl phosphorylation would be defective in X-SCID cells. Our results indicate that the absence of y c leads to an inability to phosphorylate both Jak kinases in response to IL-2. Because the complete absence of y c expression in the JT cells would also lead to abnormal binding of IL-2, one explanation of the observed defect in Jakl phosphorylation is that the IL-2RaIIL-2RP receptors expressed by the JT cells were unable to bind or internalize IL-2, leading to the defect in signal transduction. Defective IL-2 binding in X-SCID LCL has previously been described by DiSanto et al" and as well as by Ishii et al. ' However, an alternative hypothesis is suggested by our finding that, in X-SCID cell lines that express a yE protein containing a defect in the cytoplasmic domain, Jakl, phosphorylation is also abnormal (Taylor et al, manuscript in preparation). Therefore, it is likely that either Jak3 or the cytoplasmic domain of y c are necessary for Jakl phosphorylation in response to ligand binding. This confirms the previous data of Miyazaki et al," who showed that reconstitution of IL-2R function in NIH3T3 cells required the presence of both Jakl and Jak3. Additionally, natural mutations in Jak3 have recently been found to result in a SCID phenotype indistinguishable from X-SCID, indicating the importance o f Jak3 in signaling through all cytokine receptors harboring a yF chain.'x,'"
The experiments described in this report were performed in cells from a patient with a y E mutation resulting in a null phenotype. However, approximately two-thirds of X-SCID patients have heterogeneous y c chain mutations resulting in expression of a mutant yc chain prod~ct..'.".".~" B cells from these X-SCID patients would be expected to have defective IL-2 binding or defective intracellular signalling, depending on the location of the mutation. It remains to be determined whether some mutant yc products will function as dominant negatives, preventing restoration of signalling and/or normal T-cell development after transduction with the wild-type gene.
Additionally, because patients with X-SCID lack T lymphocytes, gene therapy for this disease would require transduction of the y E chain gene in a progenitor of both B and T lymphocytes. Recent data have shown that the y c gene is in fact expressed in all hematopoietic cell lineages. 
